Announcement PDF Appendix 3B - Proposed issue of securities Announcement Summary Entity name PERCHERON THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 23/10/2024 The Proposed issue is: An offer of securities under a securities purchase plan Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan ASX +security code +Security description PER ORDINARY FULLY PAID Maximum Number of +securities to be issued 25,000,000 +Record date 22/10/2024 Offer closing date 8/11/2024 +Issue date 14/11/2024 Refer to next page for full details of the announcement Appendix 3B - Proposed issue of securities 1/6 Appendix 3B - Proposed issue of securities Part 1 - Entity and announcement details 1.1 Name of +Entity PERCHERON THERAPEUTICS LIMITED We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules. If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation). 1.2 Registered Number Type Registration Number ABN 41095060745 1.3 ASX issuer code PER 1.4 The announcement is New announcement 1.5 Date of this announcement 23/10/2024 1.6 The Proposed issue is: An offer of +securities under a +securities purchase plan Appendix 3B - Proposed issue of securities 2/6 Appendix 3B - Proposed issue of securities Part 4 - Details of proposed offer under securities purchase plan Part 4A - Conditions 4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities under the +securities purchase plan issue can proceed on an unconditional basis? No Appendix 3B - Proposed issue of securities 3/6 Appendix 3B - Proposed issue of securities Part 4B - Offer details +Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued ASX +security code and description PER : ORDINARY FULLY PAID Will the proposed issue of this +security include an offer of attaching +securities? No Details of +securities proposed to be issued ASX +security code and description PER : ORDINARY FULLY PAID Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted 25,000,000 Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)? No Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)? No Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)? Yes Is the minimum acceptance unit based or dollar based? Dollar based ($) Please enter the minimum acceptance value $ 1,000 Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)? Yes Is the maximum acceptance unit based or dollar based? Dollar based ($) Please enter the maximum acceptance value $ 30,000 Appendix 3B - Proposed issue of securities 4/6 Appendix 3B - Proposed issue of securities Describe all the applicable parcels available for this offer in number of securities or dollar value The Offer will allow Eligible Shareholders to subscribe for one of the following parcels: $1000, $2,500, $5,000, $7,500, $10,000, $15,000, $20,000, $30,000 Offer price details Has the offer price been determined? Yes In what currency will the offer What is the offer price per be made? +security? AUD - Australian Dollar AUD 0.08000 Oversubscription & Scale back details Will a scale back be applied if the offer is over-subscribed? Yes Describe the scale back arrangements The Board reserves the right to scale back applications in its sole and absolute discretion. Should any scale back be necessary, it is the Board's intention that scale back arrangements will be made having regard to the pro rata shareholdings of Eligible Shareholders who apply for Shares under the Offer. Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Yes Part 4C - Timetable 4C.1 Date of announcement of +security purchase plan 23/10/2024 4C.2 +Record date 22/10/2024 4C.3 Date on which offer documents will be made available to investors 28/10/2024 4C.4 Offer open date 28/10/2024 4C.5 Offer closing date 8/11/2024 4C.7 +Issue date and last day for entity to announce results of +security purchase plan offer 14/11/2024 Appendix 3B - Proposed issue of securities 5/6 Appendix 3B - Proposed issue of securities Part 4D - Listing Rule requirements 4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements? Yes Part 4E - Fees and expenses 4E.1 Will there be a lead manager or broker to the proposed offer? No 4E.2 Is the proposed offer to be underwritten? No 4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission? No 4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer Part 4F - Further Information 4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue The Offer proceeds will be used to fund: (a) Completion of the Phase IIb avicursen clinical trial; (b) Optimisation of manufacturing processes; and (c) R&D patent protection; and (d) Working capital. 4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful? No 4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer Any country other than Australia and New Zealand 4F.3 URL on the entity's website where investors can download information about the proposed offer https://percherontx.com/ 4F.4 Any other information the entity wishes to provide about the proposed offer Appendix 3B - Proposed issue of securities 6/6